Importantly, PRKN antitumor immunity was therapeutically actionable, and a clinically approved demethylating therapy with decitabine restored epigenetically silenced endogenous PRKN expression in cancer and enabled HMGB1-dependent IFN gene expression. The gene discussed is HMGB1; the disease is cancer.